Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

14:44
10/09/16
10/09
14:44
10/09/16
14:44

Novartis reports Phase 3 data on LEE011 in breast cancer

Novartis announced that results from the pivotal Phase III MONALEESA-2 study show LEE011, or ribociclib, plus letrozole significantly extended progression-free survival compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer. The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44% over letrozole alone. The combination significantly improved PFS across all patient subgroups, regardless of disease characteristics or demographics. More than half of women with measurable disease taking LEE011 plus letrozole saw their tumor size shrink by at least 30% -- overall response rate in patients with measurable disease was 53% vs 37%. Most adverse events in the MONALEESA-2 trial were mild to moderate in severity, identified early through routine monitoring, and generally managed through dose interruption and reduction. The discontinuation rate due to adverse events in the MONALEESA-2 trial was 7.5% for LEE011 plus letrozole and 2.1% for letrozole alone. The most common grade 3/4 adverse events were as follows for LEE011 plus letrozole compared to letrozole alone: neutropenia 60% vs 1%, leukopenia 21% vs 1%, elevated alanine aminotransferase 9% vs 1%, lymphopenia 7% vs 1%, and elevated aspartate aminotransferase 6% vs 1%. Due to the significant extension of PFS and clinical benefit seen with LEE011, analysis of the primary endpoint in MONALEESA-2 was stopped early in May as recommended by the Independent Data Monitoring Committee. Follow up to measure overall survival is ongoing.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

CXO

Concho Resources

$160.41

4.22 (2.70%)

09:10
01/23/18
01/23
09:10
01/23/18
09:10
Recommendations
Concho Resources analyst commentary  »

Concho Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:09
01/23/18
01/23
09:09
01/23/18
09:09
Technical Analysis
Technical Take: Verizon trades higher after results »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

ANAB

AnaptysBio

$114.78

-0.135 (-0.12%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
AnaptysBio analyst commentary  »

AnaptysBio price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XEC

Cimarex Energy

$126.80

2.76 (2.23%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Recommendations
Cimarex Energy analyst commentary  »

Cimarex Energy price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 15

    Feb

DGX

Quest Diagnostics

$103.57

0.51 (0.49%)

09:08
01/23/18
01/23
09:08
01/23/18
09:08
Hot Stocks
Quest Diagnostics to acquire MedXM for undisclosed amount »

Quest Diagnostics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:07
01/23/18
01/23
09:07
01/23/18
09:07
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SLB

Schlumberger

$79.79

3.37 (4.41%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$60.72

2.52 (4.33%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Recommendations
Anadarko analyst commentary  »

Anadarko price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

09:06
01/23/18
01/23
09:06
01/23/18
09:06
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon says 5G trials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

TWTR

Twitter

$23.32

-0.34 (-1.44%)

09:05
01/23/18
01/23
09:05
01/23/18
09:05
Hot Stocks
SoFi names former Twitter COO Anthony Noto as CEO »

SoFi announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

HAL

Halliburton

$56.40

3.39 (6.40%)

09:05
01/23/18
01/23
09:05
01/23/18
09:05
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$91.89

0.82 (0.90%)

09:04
01/23/18
01/23
09:04
01/23/18
09:04
Hot Stocks
Procter & Gamble sees stronger earnings growth in Q4 than Q3 »

Views tax act as a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 16

    Feb

WPP

WPP

$95.32

-0.21 (-0.22%)

09:04
01/23/18
01/23
09:04
01/23/18
09:04
Downgrade
WPP rating change  »

WPP downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.94

0.23 (0.36%)

, CHTR

Charter

$370.25

4.2 (1.15%)

09:03
01/23/18
01/23
09:03
01/23/18
09:03
Hot Stocks
T-Mobile closes Layer3 TV acquisition, prepares to take on cable, satellite TV »

T-Mobile US (TMUS)…

TMUS

T-Mobile

$63.94

0.23 (0.36%)

CHTR

Charter

$370.25

4.2 (1.15%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 02

    Feb

TSLA

Tesla

$351.56

1.54 (0.44%)

09:03
01/23/18
01/23
09:03
01/23/18
09:03
Periodicals
Tesla CEO sees path to trillion-dollar company within 10 years »

"I actually see the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABC

AmerisourceBergen

$102.66

2.6 (2.60%)

09:02
01/23/18
01/23
09:02
01/23/18
09:02
Recommendations
AmerisourceBergen analyst commentary  »

AmerisourceBergen price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

XPER

Xperi

$22.50

-0.25 (-1.10%)

09:01
01/23/18
01/23
09:01
01/23/18
09:01
Hot Stocks
Xperi partners with ARCloud to bring music recognition to hybrid ratio »

Xperi Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
01/23/18
01/23
09:00
01/23/18
09:00
General news
U.S. equities are relatively subdued »

U.S. equities are…

FQVLF

First Quantum Minerals

$15.30

-0.01 (-0.07%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Downgrade
First Quantum Minerals rating change  »

First Quantum Minerals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Hot Stocks
Verizon says not considering large media acquisition »

Says remaining a partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SANM

Sanmina

$27.08

-8.35 (-23.57%)

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

JMBA

Jamba

08:59
01/23/18
01/23
08:59
01/23/18
08:59
Technical Analysis
Technical Take: Jamba down sharply on 2.1M share Block Trade »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TWTR

Twitter

$23.34

-0.31 (-1.31%)

08:57
01/23/18
01/23
08:57
01/23/18
08:57
Hot Stocks
Twitter COO Anthony Noto resigns to accept CEO role at other company »

Twitter announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

08:57
01/23/18
01/23
08:57
01/23/18
08:57
General news
Redbook Store Sales data reported »

Week of 1/20 Redbook…

SANM

Sanmina

$27.10

-8.35 (-23.55%)

08:56
01/23/18
01/23
08:56
01/23/18
08:56
Recommendations
Sanmina analyst commentary  »

Sanmina price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.